Change of Adviser

Broker Appointment and Change of Nomad

Cambridge, UK, 18 April 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Company"), the global leader in the application of gene editing technologies, today announces the appointment of Numis Securities Limited ("Numis") and RBC Capital Markets as joint brokers with immediate effect. In addition, Numis has been appointed as Nominated Adviser to the Company.

Dr. Darrin M. Disley, Chief Executive Officer, Horizon, commented: "We look forward to working with both Numis and RBC and are confident that the capabilities of these world class organisations will help us further our capital markets strategy as the business continues to grow and drive shareholder value."

- ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Dr. Darrin Disley, CEO / Richard Vellacott, CFO

Tel: +44 (0) 1223 655580

Numis Securities Limited

Michael Meade / Freddie Barnfield

Tel: +44 (0) 207 260 1000

RBC Capital Markets

Paul Tomasic / Marcus Jackson

Tel: +44 (0) 20 7653 4000

Consilium Strategic Communications (Financial Media and Investor Relations)

Amber Fennell / Jessica Hodgson / Matthew Neal / Laura Thornton

Tel: +44 (0) 20 3709 5701

Email: [email protected]

About Horizon Discovery Group plc www.horizondiscovery.com 

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon's core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon's commercial offering has been adopted by c1,400 unique research organisations in over 50 countries as well as in the Company's own R&D pipeline to support: a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".